 | |
| Company type | Public |
|---|---|
| Nasdaq: ARCT | |
| Industry | Pharmaceutical industry |
| Founded | 2013 |
| Founder | Joseph Payne and Pad Chivukula |
| Headquarters | San Diego, California, US |
Key people |
|
| Products | ARCT-810 for treatment of OTCD; received FDA Orphan Drug Status on 27 July 2019; Phase 1 Clinical Trials in Healthy Volunteers Initiated on 05 June 2020, ARCT-021 Vaccine for COVID-19; Phase 1/2 Initiated 22 July 2020, Phase 2 Initiated 9 January 2021 |
| Revenue |  $21 Million(2019)[1] |
Number of employees | 124 |
| Website | www |
Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides, and microRNA.
The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. As of 2021[update], vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase.[2]
- ^ "Arcturus Therapeutics Holdings Revenue 2012-2021 | ARCT".
- ^ Cite error: The named reference
:0was invoked but never defined (see the help page).